Lineage Cell Therapeutics (LCTX) 10-Q 9 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 09, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	876,343
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		115,804,052
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017		Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 14,550		$ 22,088
Restricted cash equivalents in escrow	5,100		0
Available for sale securities	1,220		627
Trade accounts and other receivables	360		646
Receivable from affiliates, net (Note 9)	2,706		511
Prepaid expenses and other current assets	1,589		1,777
Total current assets	25,525		25,649
Property, plant and equipment, net	5,240	[1]	5,529
Deposits and other long-term assets	1,014		1,149
Intangible assets, net	8,064	[1]	10,206
TOTAL ASSETS	193,353		142,572
CURRENT LIABILITIES
Accounts payable and accrued liabilities	5,130	[1]	7,144
Escrow liability	5,100		0
Capital lease liability, current portion	0		202
Promissory notes, current portion	124		99
Related party convertible debt, net of discount	2,555		833
Deferred revenues, current portion	621		572
Total current liabilities	13,530		8,850
LONG-TERM LIABILITIES
Deferred revenues, net of current portion	154		308
Deferred rent liabilities, net of current portion	79		50
Lease liability	1,301		1,386
Capital lease liability, net of current and other liabilities	0		310
Related party convertible debt, net of discount	0		1,032
Promissory notes, net of current portion	95		120
Other long term liabilities	9		8
TOTAL LIABILITIES	15,168		12,064
Commitments and contingencies (Note 13)
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of June 30, 2017 and December 31, 2016	0		0
Common shares, no par value, 150,000 shares authorized (Note 10); 110,876 shares issued and outstanding and 103,396 shares issued and 102,776 shares outstanding as of June 30, 2017 and December 31, 2016, respectively	334,538		317,878
Accumulated other comprehensive income (loss)	271		(738)
Accumulated deficit	(158,684)		(196,321)
Treasury stock at cost: no shares as of June 30, 2017; 620 shares as of December 31, 2016	0		(2,891)
BioTime, Inc. shareholders' equity	176,125		117,928
Noncontrolling interest	2,060		12,580
Total shareholders' equity	178,185		130,508
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	193,353		142,572
OncoCyte Corporation [Member]
CURRENT ASSETS
Equity method investment, at fair value	76,306		0
Asterias Biotherapeutics, Inc. [Member]
CURRENT ASSETS
Equity method investment, at fair value	$ 77,204		$ 100,039
[1]	Reflects the effect of the OncoCyte Deconsolidation.

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
SHAREHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, authorized (in shares)	2,000,000	2,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	110,875,610	103,396,245
Common stock, outstanding (in shares)	110,875,610	102,776,539
Treasury stock (in shares)	0	619,706

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
REVENUES:
Grant income	$ 0	$ 760	$ 11	$ 2,247
Royalties from product sales and license fees	81	86	191	286
Subscription and advertisement revenues	300	288	564	631
Sale of research products	0	132	5	176
Total revenues	381	1,266	771	3,340
Cost of sales	(5)	(95)	(62)	(320)
Gross profit	376	1,171	709	3,020
OPERATING EXPENSES:
Research and development	(6,271)	(8,938)	(12,765)	(22,671)
General and administrative	(4,423)	(6,636)	(9,524)	(18,509)
Total operating expenses	(10,694)	(15,574)	(22,289)	(41,180)
Loss from operations	(10,318)	(14,403)	(21,580)	(38,160)
OTHER INCOME/(EXPENSES):
Interest expense, net	(413)	(76)	(719)	(88)
Other income, net	2,371	237	3,098	363
Total other income/(expense), net	(5,786)	35,628	56,377	35,507
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	(16,104)	21,225	34,797	(2,653)
Deferred income tax benefit	3,877	0	0	0
NET INCOME (LOSS)	(12,227)	21,225	34,797	(2,653)
Net loss attributable to noncontrolling interests	576	3,324	2,840	10,091
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	$ (11,651)	$ 24,549	$ 37,637	$ 7,438
NET INCOME (LOSS) PER COMMON SHARE:
BASIC (in dollars per share)	$ (0.11)	$ 0.26	$ 0.35	$ 0.08
DILUTED (in dollars per share)	$ (0.11)	$ 0.26	$ 0.34	$ 0.08
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	110,874	93,240	108,804	91,831
DILUTED (in shares)	110,874	95,801	109,296	95,360
Ascendance Biotechnology, Inc. [Member]
OTHER INCOME/(EXPENSES):
BioTime's share of losses in equity method investment	$ 0	$ (98)	$ 0	$ (333)
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Gain on deconsolidation	0	49,048	0	49,048
Gain (loss) on equity method investment at fair value	3,262	(13,483)	(22,835)	(13,483)
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain on deconsolidation	0	0	71,697	0
Gain (loss) on equity method investment at fair value	$ (11,006)	$ 0	$ 5,136	$ 0

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) [Abstract]
NET INCOME (LOSS)	$ (12,227)	$ 21,225	$ 34,797	$ (2,653)
Other comprehensive income (loss), net of tax:
Change in foreign currency translation	(440)	(254)	405	(27)
Available for sale investments:
Unrealized gain (loss) on available-for-sale securities, net of taxes	304	(190)	603	(240)
COMPREHENSIVE INCOME (LOSS)	(12,363)	20,781	35,805	(2,920)
Less: Comprehensive loss attributable to non-controlling interest	576	3,324	2,840	10,091
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ (11,787)	$ 24,105	$ 38,645	$ 7,171

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income attributable to BioTime, Inc.	$ 37,637	$ 7,438
Net loss allocable to noncontrolling interests	(2,840)	(10,091)
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense, including amortization of leasehold improvements	421	748
Amortization of intangible assets	1,184	2,292
Stock-based compensation	1,930	5,593
Subsidiary shareholder expense for subsidiary warrants	0	3,125
Amortization of discount on related party convertible debt	640	245
Foreign currency remeasurement (gain) or loss and other	(1,814)	883
Gain on sale of assets	(1,754)	0
Changes in operating assets and liabilities:
Accounts and grants receivable, net	299	(54)
Deferred revenue	0	1,496
Receivables from affiliates, net of payables	332	0
Prepaid expenses and other current assets	105	(396)
Accounts payable and accrued liabilities	841	(211)
Other	(144)	(62)
Net cash used in operating activities	(17,161)	(24,559)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment and other assets	(474)	(1,384)
Restricted cash equivalents in escrow	(5,100)	0
Payments on construction in progress	0	(278)
Other	(12)	22
Cash used in investing activities	(14,484)	(10,016)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common shares	20,125	17,500
Fees paid on sale of common shares	(1,669)	(1,311)
Proceeds deposited in escrow account	5,100	0
Proceeds from exercises of stock options	29	2,015
Reimbursement from landlord on construction in progress	198	411
Shares retired to pay for employees' taxes	(31)	0
Repayment of capital lease obligation	(31)	(74)
Net proceeds from sale of common shares of subsidiary	0	171
Proceeds from issuance of related party convertible debt	299	1,019
Net cash provided by financing activities	24,020	19,731
Effect of exchange rate changes on cash and cash equivalents	87	317
NET DECREASE IN CASH AND CASH EQUIVALENTS	(7,538)	(14,527)
CASH AND CASH EQUIVALENTS:
At beginning of the period	22,088	42,229
At end of the period	14,550	27,702
Asterias Biotherapeutics [Member]
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation	0	(49,048)
Unrealized gain (loss) on equity method investment at fair value	22,835	13,483
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents	0	(8,376)
OncoCyte Corporation [Member]
Adjustments to reconcile net income attributable to BioTime, Inc. to net cash used in operating activities:
Gain on deconsolidation	(71,697)	0
Unrealized gain (loss) on equity method investment at fair value	(5,136)	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Deconsolidation of cash and cash equivalents	$ (8,898)	$ 0

Organization and Business Overv

Organization and Business Overview	6 Months Ended
	Jun. 30, 2017
Organization and Business Overview [Abstract]
Organization and Business Overview	1. Organization and Business Overview General – HyStem ® BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (“Asterias”) and OncoCyte Corporation (“OncoCyte”), which BioTime founded and, until recently, were majority-owned and consolidated subsidiaries. Asterias (NYSE MKT: AST) is developing three clinical-stage programs that have the potential to address areas of high unmet medical need in the fields of neurology (spinal cord injury) and oncology (acute myeloid leukemia and lung cancer). OncoCyte (NYSE MKT: OCX) is developing confirmatory diagnostic tests for lung cancer, breast cancer, and bladder cancer utilizing novel liquid biopsy technology. Beginning on February 17, 2017, BioTime deconsolidated OncoCyte’s financial statements and results of operations from BioTime (the “OncoCyte Deconsolidation”) (see Notes 3 and 4). Beginning on May 13, 2016, BioTime also deconsolidated Asterias financial statements and results of operations from BioTime (the “Asterias Deconsolidation”) (see Notes 3 and 5). BioTime also seeks to leverage its substantial intellectual property portfolio by advancing early-stage programs. On January 6, 2017, BioTime formed AgeX Therapeutics, Inc. (“AgeX”), a wholly-owned subsidiary, to continue development of early-stage programs. AgeX will focus on the development of regenerative medicine technologies targeting the diseases of aging and metabolic disorders. Its initial programs will focus on utilizing brown adipose tissue (“brown fat”) targeting diabetes and obesity, regenerative vascular progenitors for cardiovascular repair and our PureStem ®

Basis of Presentation, Liquidit

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract]
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies	2. Basis of Presentation, Liquidity and Summary of Significant Accounting Policies The unaudited condensed consolidated financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated balance sheet as of December 31, 2016 was derived from the audited consolidated financial statements at that date, but does not include all the information and footnotes required by GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in BioTime’s Annual Report on Form 10-K for the year ended December 31, 2016. The accompanying interim condensed consolidated financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of BioTime’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Principles of consolidation – Although beginning on February 17, 2017 and May 13, 2016, respectively, OncoCyte and Asterias financial statements and results are no longer a part of BioTime’s consolidated financial statements and results, the market value of OncoCyte and Asterias common stock, as of those respective dates, held by BioTime is reflected on BioTime’s consolidated balance sheet and the subsequent changes consolidated balance sheet and As of December 31, 2016, OncoCyte’s assets, liabilities and net assets are included in the consolidated balance sheet of BioTime, after intercompany eliminations. OncoCyte’s results of operations, comprehensive income or loss, and cash flows for the period from January 1, 2017 through February 16, 2017 are included in BioTime’s condensed consolidated statement of operations, condensed statement of comprehensive income or loss and condensed statement of cash flows for the six months ended June 30, 2017, after intercompany eliminations (see Notes 3 and 4). OncoCyte’s results are not included in BioTime’s condensed consolidated statements of operations for the three months ended June 30, 2017. OncoCyte’s results of operations, comprehensive income or loss and cash flows for the three and six months ended June 30, 2016 are included in BioTime’s condensed consolidated statement of operations, condensed statement of comprehensive income or loss and condensed statement of cash flows, after intercompany eliminations (sees Notes 3 and 4). Asterias’ results of operations, comprehensive income or loss, and cash flows for the period from January 1, 2016 through May 12, 2016 are included in BioTime’s condensed consolidated statement of operations, condensed statement of comprehensive income or loss and condensed statement of cash flows for the three and six months ended June 30, 2016. Liquidity – sufficient cash, cash equivalents and liquidity to carry out BioTime’s current operations through at least twelve months from the issuance date of the consolidated financial statements included herein. BioTime’s projected cash flows are subject to various risks and uncertainties. For example, clinical trials for BioTime’s OpRegen ® program will be funded in part with funds from grants and not from cash on hand. If the OpRegen ® program were to lose its grant funding or BioTime is unable to continue to provide working capital to fund OpRegen ® , or both, BioTime may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain adequate financing from another source that could be used for its clinical trial. The unavailability or inadequacy of financing to meet future capital needs could force BioTime to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on BioTime’s evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. BioTime cannot assure that adequate financing will be available on favorable terms, if at all. Upon completion of the offer and sale of AgeX common stock to new investors AgeX will have $10 million of cash capital to fund its operations and early-stage, pre-clinical programs (see Note 13). However, BioTime cannot assure that that adequate financing will be available to AgeX in the future to fund the AgeX programs. Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net. As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP, but BioTime continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, the value of the shares of common stock BioTime holds in Asterias and OncoCyte is marked to market using the closing prices of Asterias and OncoCyte common stock on the NYSE MKT multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the condensed consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures Basic and diluted net income (loss) per share attributable to common shareholders For the three months ended June 30, 2017, there were no potentially dilutive common share equivalents due to the net loss reported for this period presented. The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Stock options 5,035 5,644 4,459 5,679 Warrants 9,395 9,395 9,395 9,395 Recently Issued Accounting Pronouncements In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) – Scope of Modification Accounting In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgments and estimates may be required in the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). BioTime has completed an initial assessment of the new revenue recognition standard under Topic 606, which will be effective for BioTime beginning on January 1, 2018, and BioTime will be working on an implementation plan to evaluate the accounting and disclosure requirements under the new standard. Based on the work performed to date, BioTime does not expect adoption of the new standard to have a material impact on the consolidated financial statements. BioTime has not finalized its transition method for adoption.

Deconsolidation of OncoCyte and

Deconsolidation of OncoCyte and Asterias	6 Months Ended
	Jun. 30, 2017
Deconsolidation of OncoCyte and Asterias [Abstract]
Deconsolidation of OncoCyte and Asterias	3. Deconsolidation of OncoCyte and Asterias On February 17, 2017, OncoCyte issued 625,000 shares of OncoCyte common stock to certain investors who exercised their OncoCyte warrants. These warrants had been issued as part of OncoCyte’s financing that was completed on August 29, 2016. As a result of this exercise and the issuance of the 625,000 shares of OncoCyte common stock, beginning on February 17, 2017, BioTime owned less than 50% of the OncoCyte outstanding common stock and experienced a loss of control of the OncoCyte subsidiary. Under GAAP, loss of control of a subsidiary is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of the subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having the ability or being able to obtain the ability to elect a majority of the subsidiary’s Board of Directors. BioTime determined that all of these loss of control factors were present with respect to OncoCyte on February 17, 2017. Accordingly, BioTime has deconsolidated OncoCyte’s financial statements and results of operations from BioTime, effective February 17, 2017, in accordance with ASC, 810-10-40-4(c), Consolidation Beginning on February 17, 2017, BioTime is accounting for its retained noncontrolling investment in OncoCyte under the equity method of accounting and has elected the fair value option under ASC 825-10, Financial Instruments (see Note 4). In connection with the OncoCyte Deconsolidation and in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $71.7 million during the six months ended June 30, 2017, included in other income and expenses, net, in the condensed consolidated statements of operations (see Note 12). As previously reported, BioTime deconsolidated Asterias’ financial statements and results of operations from BioTime effective May 13, 2016.

Equity Method Accounting for Co

Equity Method Accounting for Common Stock of OncoCyte, at fair value	6 Months Ended
	Jun. 30, 2017
Equity Method Accounting for Common Stock of OncoCyte, at fair value [Abstract]
Equity Method Accounting for Common Stock of OncoCyte, at fair value	4. Equity Method Accounting for Common Stock of OncoCyte, at fair value BioTime elected to account for its 14.7 million shares of OncoCyte common stock The unaudited condensed results of operations for the three and six months ended June 30, 2017 and 2016 are summarized below (in thousands): Three Months Ended June 30, Six Months Ended June 30, For the Period January 1, 2017 to February 16, 2017 2017 2016 2017 2016 Condensed Statements of Operations (unaudited) (1) Research and development expense $ 1,997 $ 1,195 $ 3,881 $ 2,884 $ 798 General and administrative expense 1,115 1,067 3,158 2,081 377 Sales and marketing expense 477 270 1,132 499 213 Loss from operations (3,589 ) (2,532 ) (8,121 ) (5,464 ) (1,388 ) Net loss $ (3,804 ) $ (2,543 ) $ (8,509 ) $ (5,471 ) $ (1,392 ) (1)

Equity Method Accounting for 11

Equity Method Accounting for Common Stock of Asterias, at fair value	6 Months Ended
	Jun. 30, 2017
Equity Method Accounting for Common Stock of Asterias, at fair value [Abstract]
Equity Method Accounting for Common Stock of Asterias, at fair value	5. Equity Method Accounting for Common Stock of Asterias, at fair value BioTime elected to account for its 21.7 million shares of Asterias common stock The unaudited condensed results of operations for the three and six months ended June 30, 2017 and 2016 and for the period from January 1, 2016 through May 12, 2016 are summarized below (in thousands): Three Months Ended June 30, Six Months Ended June 30, For the Period January 1, 2016 to May 12, 2016 2017 2016 2017 2016 Condensed Statements of Operations (unaudited) (1): Total revenue $ 316 $ 1,532 $ 2,326 $ 3,126 $ 2,354 Gross profit 298 1,526 2,256 3,067 2,301 Loss from operations (8,533 ) (7,074 ) (17,640 ) (18,166 ) (13,944 ) Net loss $ (8,728 ) $ (5,159 ) $ (15,015 ) $ (15,496 ) $ (13,113 ) (1)

Property, plant and equipment,

Property, plant and equipment, net	6 Months Ended
	Jun. 30, 2017
Property, plant and equipment, net [Abstract]
Property, plant and equipment, net	6. Property, plant and equipment, net At June 30, 2017 and December 31, 2016, property, plant and equipment was comprised of the following (in thousands): June 30, 2017 (unaudited) (1) December 31, 2016 Equipment, furniture and fixtures $ 4,001 $ 4,718 Leasehold improvements 4,016 3,791 Accumulated depreciation and amortization (2,777 ) (2,980 ) Property, plant and equipment, net $ 5,240 $ 5,529 (1) Depreciation expense, including amortization of leasehold improvements, amounted to $421,000 and $748,000 for the six months ended June 30, 2017 and 2016, respectively.

Intangible assets, net

Intangible assets, net	6 Months Ended
	Jun. 30, 2017
Intangible assets, net [Abstract]
Intangible assets, net	7. Intangible assets, net At June 30, 2017 and December 31, 2016, intangible assets, primarily consisting of acquired patents, and accumulated amortization were as follows (in thousands): June 30, 2017 (unaudited) (1) December 31, 2016 Intangible assets $ 23,294 $ 25,703 Accumulated amortization (15,230 ) (15,497 ) Intangible assets, net $ 8,064 $ 10,206 (1) BioTime recognized $1.2 million and $2.3 million in amortization expense of intangible assets, included in research and development expenses, during the six months ended June 30, 2017 and 2016, respectively.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	6 Months Ended
	Jun. 30, 2017
Accounts Payable and Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities	8. Accounts Payable and Accrued Liabilities At June 30, 2017 and December 31, 2016, accounts payable and accrued liabilities consisted of the following (in thousands): June 30, 2017 (unaudited) (1) December 31, 2016 Accounts payable $ 752 $ 1,593 Accrued expenses 2,385 3,212 Accrued compensation 1,461 1,904 Other current liabilities 532 435 Total $ 5,130 $ 7,144 (1)

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	9. Related Party Transactions Related Party Convertible Debt Cell Cure issued certain convertible promissory notes (the “Convertible Notes”) to Cell Cure shareholders other than BioTime. The functional currency of Cell Cure is the Israeli New Shekel however the Convertible Notes are payable in United States dollars. Consequently, at each balance sheet date, Cell Cure remeasures the Convertible Notes issued to BioTime and other Cell Cure shareholders using the current exchange rate at that date pursuant to ASC 830, Foreign Currency Matters. These foreign currency remeasurement gains and losses are included in other income and expense, net. The Convertible Notes bear a stated interest rate of 3% per annum. The total outstanding principal balance of the Convertible Notes, with accrued interest, is due and payable on various maturity dates in July 2017 and September 2017, and in February 2019 through August 2019. The outstanding principal balance of the Convertible Notes with accrued interest is convertible into Cell Cure ordinary shares at a fixed conversion price of $20.00 per share, at the election of the holder, at any time prior to maturity. Any conversion of the Convertible Notes must be settled with Cell Cure ordinary shares and not with cash. The conversion feature of the Convertible Notes issued is not accounted for as an embedded derivative under the provisions of ASC 815, Derivatives and Hedging since it is not a freestanding financial instrument and the underlying Cell Cure ordinary shares are not readily convertible into cash. Accordingly, the Convertible Notes are accounted for under ASC 470-20, Debt with Conversion and Other Options (ASC 470-20) . Under ASC 470-20, BioTime determined that a beneficial conversion feature (“BCF”) was present on the issuance dates of the Convertible Notes. A conversion feature is beneficial if, on the issuance dates, the effective conversion price is less than the fair value of the issuer’s capital stock. Since the effective conversion price of $20.00 per share is less than the estimated range of fair values from $28.00 per share to $40.00 per share of Cell Cure ordinary shares on the dates the Convertible Notes were issued, a beneficial conversion feature, equal to the intrinsic value ranging from $8 per share to $20 per share, is present. In accordance with ASC 470-20-30-8, if the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. The BCF is recorded as an addition to equity with a corresponding debt discount on the Convertible Notes’ issuance date. This debt discount is amortized to interest expense using the effective interest method over the three-year term of the debt, representing an approximate effective annual interest rate between 11% and 23%. As of June 30, 2017, certain tranches of the Convertible Notes had matured and were due and payable to Cell Cure shareholders other than BioTime. However, as further discussed in Note 14, on July 10, 2017, BioTime purchased all of the outstanding Convertible Notes held by H adasit Bio-Holdings Ltd. (“HBL”), a Cell Cure shareholder that held substantially all of the Convertible Notes issued by Cell Cure to shareholders other than BioTime Shared Facilities and Service Agreements with Affiliates The receivables from affiliates shown on the condensed consolidated balance sheet as of June 30, 2017 primarily represents amounts owed to BioTime from OncoCyte under a Shared Facilities and Service Agreement (the “Shared Facilities Agreement”). Under the terms of the Shared Facilities Agreement, BioTime allows OncoCyte to use BioTime’s premises and equipment located at Alameda, California for the sole purpose of conducting business. BioTime also provides accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte. BioTime may also provide the services of attorneys, accountants, and other professionals who may also provide professional services to BioTime and its other subsidiaries. BioTime also has provided OncoCyte with the services of laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte at the premises. BioTime charges OncoCyte a “Use Fee” for services provided and usage of BioTime facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates to OncoCyte costs incurred, including costs for services of BioTime employees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. The allocation of costs depends on key cost drivers, including actual documented use, square footage of facilities used, time spent, costs incurred by BioTime for OncoCyte, or upon proportionate usage by BioTime and OncoCyte, as reasonably estimated by BioTime. BioTime, at its discretion, has the right to charge OncoCyte a 5% markup on such allocated costs although BioTime elected not to charge this markup from the inception of the Shared Facilities Agreement through December 31, 2015. For allocated costs incurred beginning on January 1, 2016, BioTime is charging the 5% markup. The allocated cost of BioTime employees and contractors who provide services is based upon records maintained of the number of hours of such personnel devoted to the performance of services. The Use Fee is determined and invoiced to OncoCyte on a quarterly basis for each calendar quarter of each calendar year. If the Shared Facilities Agreement terminates prior to the last day of a billing period, the Use Fee will be determined for the number of days in the billing period elapsed prior to the termination of the Shared Facilities Agreement. Each invoice will be payable in full by OncoCyte within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime employees from OncoCyte funds available for such purpose, rather than from the unavailability of sufficient funds legally available for payment or from an act, omission, or delay by any employee or agent of OncoCyte. Through June 30, 2017, BioTime has not charged OncoCyte any interest. In addition to the Use Fees, OncoCyte will reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte, provided that invoices documenting such costs are delivered to OncoCyte with each invoice for the Use Fee. BioTime will have no obligation to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte, and if any such supplies, goods, materials or services are obtained for OncoCyte, BioTime may arrange for the suppliers to invoice OncoCyte directly. The Shared Facilities Agreement will remain in effect, unless either party gives the other party written notice stating that the Shared Facilities Agreement will terminate on December 31 of that year, or unless the agreement is otherwise terminated under another provision of the agreement. As of June 30, 2017, BioTime has a $2.5 million receivable from OncoCyte included in receivable from affiliates, net, on account of Use Fees incurred by OncoCyte under the Shared Facilities Agreement. Since these amounts are due and payable within 30 days of being invoiced, the receivable is classified as a current asset. The remaining $0.2 million receivable from affiliate is due from Ascendance Biotechnology, Inc. (“Ascendance”), an equity method investee of BioTime, net of allowance for doubtful accounts, for similar shared services performed by BioTime for Ascendance. BioTime has a similar Shared Facilities Agreement with Asterias and as of June 30, 2017 there was no net receivable from Asterias. As of December 31, 2016, BioTime had a receivable from Asterias of approximately $0.3 million which was paid during the six months ended June 30, 2017. BioTime accounts for receivables from affiliates, net of payables to affiliates, if any, for similar shared services and other transactions BioTime’s consolidated subsidiaries may enter into with nonconsolidated affiliates. BioTime and the affiliates record those receivables and payables on a net basis since BioTime and the affiliate have a legal right of offset of the receivable and the payable, intend to offset those receivables and payables, and settle the balances net by having the party that owes the other party pay the net balance owed. Other related party transaction BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost.

Shareholders' Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2017
Shareholders' Equity [Abstract]
Shareholders' Equity	10. Shareholders’ Equity Preferred Shares BioTime is authorized to issue 2,000,000 preferred shares. The preferred shares may be issued in one or more series as the board of directors may determine by resolution. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issuance of shares of that series. There are no preferred shares issued and outstanding. Common Shares BioTime is authorized to issue 150,000,000 common shares with no par value. An amendment of BioTime’s Articles of Incorporation increasing BioTime’s authorized common shares from 125,000,000 to 150,000,000 (the “Articles Amendment”) was approved by BioTime shareholders at the 2016 Annual Meeting of Shareholders and a Certificate of Amendment to BioTime’s Articles of Incorporation was subsequently filed with the State of California to reflect the increase. While BioTime believes that shareholder approval of the Articles Amendment was properly obtained, there may be uncertainty with respect to the validity or effectiveness of that approval because certain common shares held by brokers or other nominees and with respect to which the beneficial owners had not provided voting instructions were voted by the brokers or nominees in favor of the Articles Amendment in accordance with the rules of the New York Stock Exchange. Certain statements made in BioTime’s definitive proxy statement for the 2016 Annual Meeting of Shareholders were inconsistent with the voting rights of the brokers and nominees who did not receive voting instructions from the beneficial owners of the shares. As a result, BioTime has re-submitted the Articles Amendment for shareholder approval at its 2017 Annual Meeting of Shareholders, which was held on August 9, 2017, and the shareholders reaffirmed and approved the Articles Amendment for 150,000,000 authorized shares on that date (see Note 14). BioTime will file a Certificate of Amendment to its Articles of Incorporation which will supersede the Certificate of Amendment filed during June 2016, which will confirm that the authorized number of common shares is 150,000,000. As of June 30, 2017, BioTime had 110,875,610 issued and outstanding common shares and no outstanding treasury stock. 103,396,245 102,776,539 619,706 n February 17, 2017, and in connection with the OncoCyte Deconsolidation, those treasury shares are considered to be issued and outstanding BioTime common shares. During February 2017, BioTime sold 7,453,704 common shares in an underwritten public offering. The offering price to the public was $2.70 per share and net proceeds to BioTime were approximately $18.5 million, after deducting underwriting discounts, commissions and expenses related to the financing. On April 6, 2017, BioTime, entered into a Controlled Equity Offering SM BioTime will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreement may be terminated by Cantor Fitzgerald or BioTime at any time upon notice to the other party, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in BioTime’s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. On July 10, 2017, BioTime issued 4,924,542 common shares valued at $15.2 million to purchase Cell Cure ordinary shares and Convertible Notes held by certain Cell Cure shareholders. See Notes 9 and 14. Transactions with Noncontrolling Interests of LifeMap Sciences and LifeMap Solutions On June 6, 2017, BioTime increased its ownership in LifeMap Sciences from 78% to 82% and obtained a direct 100% ownership interest in LifeMap Solutions, of which 78% was previously indirectly owned by BioTime through LifeMap Sciences, for settlement and cancellation of certain intercompany debt owed by LifeMap Sciences. This transaction resulted in a $3.1 million equity transfer, at carrying value, between BioTime, LifeMap Sciences and LifeMap Solutions recorded in shareholders’ equity as of June 30, 2017, in accordance with the guidance under ASC 810-10-45-23. BioTime accounts for a change in ownership interests in its subsidiaries that does not result in a change of control of the subsidiary by BioTime under the provisions of ASC 810-10-45-23. Under this guidance, changes in a controlling shareholder’s ownership interest that do not result in a change of control, as defined by GAAP, in the subsidiary are accounted for as equity transactions. Thus, if the controlling shareholder retains control, no gain or loss is recognized in the statement of operations of the controlling shareholder. Similarly, the controlling shareholder will not record any additional acquisition adjustments to reflect its subsequent purchases of additional shares in the subsidiary if there is no change of control. Only a proportional and immediate transfer of carrying value between the controlling and the noncontrolling shareholders occurs based on the respective ownership percentages.

Stock Option Plans

Stock Option Plans	6 Months Ended
	Jun. 30, 2017
Stock Option Plans [Abstract]
Stock Option Plans	11. Stock Option Plans BioTime adopted the 2012 Equity Incentive Plan, as amended (the “2012 Plan”), under which BioTime reserved 16,000,000 common shares for the grant of stock options, restricted stock, restricted stock units and stock appreciation rights. A summary of BioTime’s 2012 Plan activity and related information follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price of Options December 31, 2016 2,894 6,958 100 $ 3.60 Increase to the 2012 Plan option pool 6,000 - - - Options granted (1,509 ) 1,509 - 3.12 Options exercised - (9 ) - 2.66 Restricted stock units vested - - (25 ) n/a Options forfeited/cancelled 410 (590 ) - 4.02 June 30, 2017 7,795 7,868 75 $ 3.49 Options exercisable at June 30, 2017 3,811 $ 3.74 Stock-Based Compensation Expense The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions noted in the following table Six Months Ended June 30, 2017 2016 Expected life (in years) 6.08 6.07 Risk-free interest rates 1.92 % 1.45 % Volatility 59.80 % 61.78 % Dividend yield - % - % Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 166 $ 579 $ 496 $ 1,785 General and administrative 739 1,641 1,434 3,808 Total stock-based compensation expense $ 905 $ 2,220 $ 1,930 $ 5,593

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Taxes [Abstract]
Income Taxes	12. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting For items that BioTime cannot reliably estimate on an annual basis (principally unrealized gains or losses generated on its Asterias and OncoCyte shares due to the changes in the respective stock prices of Asterias and OncoCyte), BioTime uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of that item, including the use of all available net operating losses and other credits or deferred tax assets. In connection with the deconsolidation of Asterias and OncoCyte (see Note 3), although neither deconsolidation was a taxable transaction to BioTime and did not create a current income tax payment obligation to BioTime, the market value of the respective shares BioTime holds creates a deferred tax liability to BioTime based on the closing price of the security, less the tax basis of the security BioTime has in such shares. The deferred tax liability generated by the Asterias and OncoCyte shares that BioTime holds as of June 30, 2017, is a source of future taxable income to BioTime, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realization of its deferred tax assets to the extent of those deferred tax liabilities. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. For federal income tax purposes, as a result of the deconsolidation of Asterias and OncoCyte as discussed in Note 3 and the deferred tax liabilities generated from the Asterias and OncoCyte share market values from their respective deconsolidation dates, including the changes to those deferred tax liabilities due to changes in the Asterias and OncoCyte stock price through June 30, 2017, BioTime’s deferred tax assets exceeded its deferred tax liabilities as of June 30, 2017. Accordingly, as of June 30, 2017, for federal income tax purposes, BioTime established a full valuation allowance on its deferred tax assets as it is not more likely than not that the deferred tax assets will be realized. Consequently, the $3.9 million tax provision recognized in the first quarter of 2017 was reversed in the second quarter of 2017, resulting in no tax provision or benefit for the six months ended June 30, 2017. For state income tax purposes, BioTime has a full valuation allowance on its state deferred tax assets as of June 30, 2017 and December 31, 2016 and, accordingly, no state tax provision or benefit was recorded for any period presented. BioTime established a full valuation allowance as of December 31, 2016 and 2015 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. Accordingly, BioTime did not record any provision or benefit for income taxes for the three and six months ended June 30, 2016.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Alameda Lease On December 10, 2015, BioTime entered into a lease for approximately 30,795 square feet of rentable space in two buildings located in an office park in Alameda, California (the “New Alameda Lease”). The term of the New Alameda Lease is seven years and BioTime has an option to renew the term for an additional five years. BioTime moved into the facility and the term of the New Alameda Lease commenced effective February 1, 2016. Base rent under the New Alameda Lease commenced on February 1, 2016 at $64,670 per month, and will increase by approximately 3% annually on every February 1 thereafter during the lease term. The lease payments allocated to the landlord liability are amortized as debt service on that liability over the lease term. Litigation – General BioTime will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, BioTime discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts BioTime has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations. Indemnification In the normal course of business, BioTime may provide indemnifications of varying scope under BioTime’s agreements with other companies or consultants, typically BioTime’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of BioTime’s products and services. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands for indemnification. BioTime also maintains various liability insurance policies that limit BioTime’s financial exposure. As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded any liabilities for these agreements as of June 30, 2017 and December 31, 2016. AgeX Therapeutics Restricted Cash and Escrow Liability On January 6, 2017, BioTime formed AgeX Therapeutics, Inc., a wholly-owned subsidiary, to continue development of early-stage programs. AgeX will focus on the development of technology primarily related to regenerative medicine relevant to diseases of aging, technologies related to metabolic disorders based on the properties of brown fat, and therapies for vascular diseases, defects, and disorders. AgeX may pursue other early-stage programs using BioTime’s PureStem ® On June 12, 2017, AgeX entered into an Escrow Agreement with Wells Fargo Bank (“Escrow Agent”) to hold funds deposited by potential new investors in AgeX (the “AgeX Investors”) for the purchase of AgeX common stock in a private offering. At June 30, 2017, the escrowed funds were restricted as to use for operating purposes to both AgeX and BioTime until disbursed by the Escrow Agent in accordance with directions from AgeX. After the conditions to the sale of AgeX common stock are met, and the funds held in escrow are disbursed to AgeX, shares of AgeX common stock will be issued to the AgeX Investors. If the conditions of the sale are not satisfied, the escrow funds will be returned to the AgeX Investors. AgeX has control and responsibility to direct the investments in the escrow account, including disbursement requests in accordance with the Escrow Agreement. Any interest earned on the escrow account accrues to AgeX, regardless to whom the escrow funds are disbursed. As of June 30, 2017, AgeX had received $5.1 million in the escrow account from certain AgeX Investors but the conditions required by AgeX for the sale of the AgeX common stock had not been satisfied as of that date. Accordingly, AgeX recorded the $5.1 million as a restricted cash equivalent and a corresponding escrow liability on the condensed consolidated balance sheet at June 30, 2017. Second Amended and Restated License Agreement On June 15, 2017, Cell Cure entered into a Second Amended and Restated License Agreement (the “License Agreement”) with Hadasit Medical Research Services and Development Ltd. (“Hadasit”), the commercial arm and a wholly-owned subsidiary of Hadassah Medical Organization. Pursuant to the License Agreement, Hadasit granted Cell Cure an exclusive, worldwide, royalty bearing license (with the right to grant sublicenses) in its intellectual property portfolio of materials and technology related to human stem cell derived photoreceptor cells and retinal pigment epithelial cells (the “Licensed IP”), to use, commercialize and exploit any part thereof, in any manner whatsoever in the fields of the development and exploitation of (i) human stem cell derived photoreceptor cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders, and (ii) human stem cell derived retinal pigment epithelial cells, solely for use in cell therapy for the diagnosis, amelioration, prevention and treatment of eye disorders. As consideration for the Licensed IP, Cell Cure will pay a small one-time lump sum payment, a royalty in the mid single digits of net sales from sales of Licensed IP by any invoicing entity, and . In addition, Cell Cure will pay Hadasit an annual minimal non-refundable royalty, which will become due and payable the first January 1 following the completion of services to Cell Cure by a research laboratory. Cell Cure agreed to pay Hadasit non-refundable milestone payments upon the recruitment of the first patient for the first Phase IIB clinical trial, upon the enrollment of the first patient in the first Phase III clinical trials, upon delivery of the report for the first Phase III clinical trials, upon the receipt of an NDA or marketing approval in the European Union, whichever is the first to occur, and upon the first commercial sale in the United States or European Union, whichever is the first to occur. Such milestones, in the aggregate, may be up to $3.5 million. As of June 30, 2017, Cell Cure had not accrued any milestone payments under the License Agreement. The License Agreement terminates upon the expiration of Cell Cure’s obligation to pay royalties for all licensed products, unless earlier terminated. In addition, the License Agreement may be terminated by (i) Hadasit if, among other reasons, Cell Cure fails to continue the clinical development of the Licensed IP or fails to take actions to commercialize or sell the Licensed IP over any consecutive 12 month period, and (ii) by either party for (a) a material breach which remains uncured following a cure period, or (b) the granting of a winding-up order in respect of the other party, or upon an order being granted against the other party for the appointment of a receiver or a liquidator in respect of a substantial portion of such other party’s assets. The License Agreement also contains mutual confidentiality obligations of Cell Cure and Hadasit, and indemnification obligations of Cell Cure.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On July 10, 2017, BioTime purchased all of the outstanding Cell Cure Convertible Notes and Cell Cure ordinary shares held by H adasit Bio-Holdings Ltd. (“HBL”), a Cell Cure shareholder that owned 21.2% of the issued and outstanding Cell Cure ordinary shares and substantially all of the Cell Cure Convertible Notes issued by Cell Cure shareholders other than BioTime Consolidation Other Presentation Matters, On August 8, 2017, the Israel Innovation Authority (the "IIA") approved a grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2.0 million) for the developement of OpRegen ® On August 9, 2017, BioTime shareholders reaffirmed and approved the Articles Amendment for 150,000,000 authorized shares (see Note 10). BioTime will file a Certificate of Amendment to its Articles of Incorporation which will confirm that the authorized number of common shares is 150,000,000 and will supersede the Certificate of Amendment filed during June 2016.

Basis of Presentation, Liquid21

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation – Although beginning on February 17, 2017 and May 13, 2016, respectively, OncoCyte and Asterias financial statements and results are no longer a part of BioTime’s consolidated financial statements and results, the market value of OncoCyte and Asterias common stock, as of those respective dates, held by BioTime is reflected on BioTime’s consolidated balance sheet and the subsequent changes consolidated balance sheet and As of December 31, 2016, OncoCyte’s assets, liabilities and net assets are included in the consolidated balance sheet of BioTime, after intercompany eliminations. OncoCyte’s results of operations, comprehensive income or loss, and cash flows for the period from January 1, 2017 through February 16, 2017 are included in BioTime’s condensed consolidated statement of operations, condensed statement of comprehensive income or loss and condensed statement of cash flows for the six months ended June 30, 2017, after intercompany eliminations (see Notes 3 and 4). OncoCyte’s results are not included in BioTime’s condensed consolidated statements of operations for the three months ended June 30, 2017. OncoCyte’s results of operations, comprehensive income or loss and cash flows for the three and six months ended June 30, 2016 are included in BioTime’s condensed consolidated statement of operations, condensed statement of comprehensive income or loss and condensed statement of cash flows, after intercompany eliminations (sees Notes 3 and 4). Asterias’ results of operations, comprehensive income or loss, and cash flows for the period from January 1, 2016 through May 12, 2016 are included in BioTime’s condensed consolidated statement of operations, condensed statement of comprehensive income or loss and condensed statement of cash flows for the three and six months ended June 30, 2016.
Liquidity	Liquidity – sufficient cash, cash equivalents and liquidity to carry out BioTime’s current operations through at least twelve months from the issuance date of the consolidated financial statements included herein. BioTime’s projected cash flows are subject to various risks and uncertainties. For example, clinical trials for BioTime’s OpRegen ® program will be funded in part with funds from grants and not from cash on hand. If the OpRegen ® program were to lose its grant funding or BioTime is unable to continue to provide working capital to fund OpRegen ® , or both, BioTime may be required to delay, postpone, or cancel its clinical trials or limit the number of clinical trial sites, or otherwise reduce or curtail its operations unless it is able to obtain adequate financing from another source that could be used for its clinical trial. The unavailability or inadequacy of financing to meet future capital needs could force BioTime to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on BioTime’s evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, and projection of future costs, revenues, and rates of expenditure. BioTime cannot assure that adequate financing will be available on favorable terms, if at all. Upon completion of the offer and sale of AgeX common stock to new investors AgeX will have $10 million of cash capital to fund its operations and early-stage, pre-clinical programs (see Note 13). However, BioTime cannot assure that that adequate financing will be available to AgeX in the future to fund the AgeX programs.
Equity method accounting for Asterias and OncoCyte, at fair value	Equity method accounting for Asterias and OncoCyte, at fair value – BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net. As further discussed in Notes 4 and 5, BioTime has elected to account for its Asterias and OncoCyte shares at fair value using the equity method of accounting because beginning on May 13, 2016 and February 17, 2017, the respective dates on which BioTime deconsolidated Asterias and OncoCyte, BioTime has not had control of Asterias and OncoCyte, as defined by GAAP, but BioTime continues to exercise significant influence over Asterias and OncoCyte. Under the fair value method, the value of the shares of common stock BioTime holds in Asterias and OncoCyte is marked to market using the closing prices of Asterias and OncoCyte common stock on the NYSE MKT multiplied by the number of shares of Asterias and OncoCyte held by BioTime, with changes in the fair value of the Asterias and OncoCyte shares included in other income and expenses, net, in the condensed consolidated statements of operations. The Asterias and OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures
Basic and diluted net income (loss) per share attributable to common shareholders	Basic and diluted net income (loss) per share attributable to common shareholders For the three months ended June 30, 2017, there were no potentially dilutive common share equivalents due to the net loss reported for this period presented. The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Stock options 5,035 5,644 4,459 5,679 Warrants 9,395 9,395 9,395 9,395
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718) – Scope of Modification Accounting In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgments and estimates may be required in the revenue recognition process than are required under existing GAAP. The revised revenue standard is effective for public entities for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients; or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). BioTime has completed an initial assessment of the new revenue recognition standard under Topic 606, which will be effective for BioTime beginning on January 1, 2018, and BioTime will be working on an implementation plan to evaluate the accounting and disclosure requirements under the new standard. Based on the work performed to date, BioTime does not expect adoption of the new standard to have a material impact on the consolidated financial statements. BioTime has not finalized its transition method for adoption.

Basis of Presentation, Liquid22

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies [Abstract]
Antidilutive securities excluded from computation of earnings per share	The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Stock options 5,035 5,644 4,459 5,679 Warrants 9,395 9,395 9,395 9,395

Equity Method Accounting for 23

Equity Method Accounting for Common Stock of OncoCyte, at fair value (Tables)	6 Months Ended
	Jun. 30, 2017
OncoCyte [Member]
Schedule of Equity Method Investments [Line Items]
Unaudited results of operations	The unaudited condensed results of operations for the three and six months ended June 30, 2017 and 2016 are summarized below (in thousands): Three Months Ended June 30, Six Months Ended June 30, For the Period January 1, 2017 to February 16, 2017 2017 2016 2017 2016 Condensed Statements of Operations (unaudited) (1) Research and development expense $ 1,997 $ 1,195 $ 3,881 $ 2,884 $ 798 General and administrative expense 1,115 1,067 3,158 2,081 377 Sales and marketing expense 477 270 1,132 499 213 Loss from operations (3,589 ) (2,532 ) (8,121 ) (5,464 ) (1,388 ) Net loss $ (3,804 ) $ (2,543 ) $ (8,509 ) $ (5,471 ) $ (1,392 ) (1)

Equity Method Accounting for 24

Equity Method Accounting for Common Stock of Asterias, at fair value (Tables)	6 Months Ended
	Jun. 30, 2017
Asterias Biotherapeutics [Member]
Schedule of Equity Method Investments [Line Items]
Unaudited results of operations	The unaudited condensed results of operations for the three and six months ended June 30, 2017 and 2016 and for the period from January 1, 2016 through May 12, 2016 are summarized below (in thousands): Three Months Ended June 30, Six Months Ended June 30, For the Period January 1, 2016 to May 12, 2016 2017 2016 2017 2016 Condensed Statements of Operations (unaudited) (1): Total revenue $ 316 $ 1,532 $ 2,326 $ 3,126 $ 2,354 Gross profit 298 1,526 2,256 3,067 2,301 Loss from operations (8,533 ) (7,074 ) (17,640 ) (18,166 ) (13,944 ) Net loss $ (8,728 ) $ (5,159 ) $ (15,015 ) $ (15,496 ) $ (13,113 ) (1)

Property, plant and equipment25

Property, plant and equipment, net (Tables)	6 Months Ended
	Jun. 30, 2017
Property, plant and equipment, net [Abstract]
Property, plant and equipment, net	At June 30, 2017 and December 31, 2016, property, plant and equipment was comprised of the following (in thousands): June 30, 2017 (unaudited) (1) December 31, 2016 Equipment, furniture and fixtures $ 4,001 $ 4,718 Leasehold improvements 4,016 3,791 Accumulated depreciation and amortization (2,777 ) (2,980 ) Property, plant and equipment, net $ 5,240 $ 5,529 (1)

Intangible assets, net (Tables)

Intangible assets, net (Tables)	6 Months Ended
	Jun. 30, 2017
Intangible assets, net [Abstract]
Intangible assets	At June 30, 2017 and December 31, 2016, intangible assets, primarily consisting of acquired patents, and accumulated amortization were as follows (in thousands): June 30, 2017 (unaudited) (1) December 31, 2016 Intangible assets $ 23,294 $ 25,703 Accumulated amortization (15,230 ) (15,497 ) Intangible assets, net $ 8,064 $ 10,206 (1)

Accounts Payable and Accrued 27

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable and accrued liabilities	At June 30, 2017 and December 31, 2016, accounts payable and accrued liabilities consisted of the following (in thousands): June 30, 2017 (unaudited) (1) December 31, 2016 Accounts payable $ 752 $ 1,593 Accrued expenses 2,385 3,212 Accrued compensation 1,461 1,904 Other current liabilities 532 435 Total $ 5,130 $ 7,144 (1)

Stock Option Plans (Tables)

Stock Option Plans (Tables)	6 Months Ended
	Jun. 30, 2017
Stock Option Plans [Abstract]
Summary of stock option activity	A summary of BioTime’s 2012 Plan activity and related information follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price of Options December 31, 2016 2,894 6,958 100 $ 3.60 Increase to the 2012 Plan option pool 6,000 - - - Options granted (1,509 ) 1,509 - 3.12 Options exercised - (9 ) - 2.66 Restricted stock units vested - - (25 ) n/a Options forfeited/cancelled 410 (590 ) - 4.02 June 30, 2017 7,795 7,868 75 $ 3.49 Options exercisable at June 30, 2017 3,811 $ 3.74
Schedule of weighted average assumptions to calculate fair value of stock options	The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions noted in the following table Six Months Ended June 30, 2017 2016 Expected life (in years) 6.08 6.07 Risk-free interest rates 1.92 % 1.45 % Volatility 59.80 % 61.78 % Dividend yield - % - %
Schedule of stock based compensation expense	Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Research and development $ 166 $ 579 $ 496 $ 1,785 General and administrative 739 1,641 1,434 3,808 Total stock-based compensation expense $ 905 $ 2,220 $ 1,930 $ 5,593

Organization and Business Ove29

Organization and Business Overview (Details)	6 Months Ended
	Jun. 30, 2017SectorTechnologySubsidiaryProgram
Organization and Business Overview [Abstract]
Number of primary sectors | Sector	3
Number of platform technologies | Technology	2
Number of subsidiaries | Subsidiary	2
Number of clinical stage programs | Program	3

Basis of Presentation, Liquid30

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Liquidity [Abstract]
Accumulated deficit	$ 158,684		$ 158,684		$ 196,321
Shareholders' equity	$ 176,125		176,125		$ 117,928
Cash capital from the sale of common stock			$ 20,125	$ 17,500
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	110,874	95,801	109,296	95,360
Asterias Biotherapeutics and OncoCyte [Member]
Liquidity [Abstract]
Cash and cash equivalents, available for sale securities, combined value	$ 153,500		$ 153,500
AgeX [Member]
Liquidity [Abstract]
Cash capital from the sale of common stock			10,000
Parent [Member]
Liquidity [Abstract]
Accumulated deficit	(159,000)		(159,000)
Working capital	12,000		12,000
Shareholders' equity	178,000		178,000
Cash, cash equivalents and available for sale securities	$ 15,800		$ 15,800
Treasury Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	0	2,400,000	164,000	3,400,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	0	164,000	328,000	94,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average dilutive common shares used to compute diluted net income per common share (in shares)	0	164,000	328,000	94,000
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares)	5,035,000	5,644,000	4,459,000	5,679,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares excluded from computation of diluted income (loss) per share (in shares)	9,395,000	9,395,000	9,395,000	9,395,000

Deconsolidation of OncoCyte a31

Deconsolidation of OncoCyte and Asterias (Details) - OncoCyte [Member] - USD ($) $ in Thousands	Feb. 17, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Noncontrolling Interest [Line Items]
Issuance of common stock to certain investors upon exercise of warrants (in shares)	625,000
Gain on deconsolidation		$ 0	$ 0	$ 71,697	$ 0
Maximum [Member]
Noncontrolling Interest [Line Items]
Equity method ownership percentage	50.00%

Equity Method Accounting for 32

Equity Method Accounting for Common Stock of OncoCyte, at fair value (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions		2 Months Ended	3 Months Ended		6 Months Ended
		Feb. 16, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Feb. 17, 2017	Dec. 31, 2016	May 13, 2016
Asterias Biotherapeutics, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Common stock, outstanding (in shares)										21.7
Fair value on investment			$ 77,200		$ 77,200				$ 100,000
Price per share on NYSE MKT (in dollars per share)			$ 3.55		$ 3.55		$ 3.40		$ 4.60
Condensed Statements of Operations (unaudited) [Abstract]
Loss from operations	[1]	$ (13,944)	$ (8,533)	$ (7,074)	$ (17,640)	$ (18,166)
Net loss	[1]	(13,113)	(8,728)	(5,159)	(15,015)	(15,496)
OncoCyte [Member]
Schedule of Equity Method Investments [Line Items]
Common stock, outstanding (in shares)								14.7
Fair value on investment			$ 76,300		$ 76,300			$ 71,200
Price per share on NYSE MKT (in dollars per share)			$ 5.20		$ 5.20		$ 5.95	$ 4.85
Unrealized gains (loss) on equity method investment			$ (11,000)		$ 5,100
Condensed Statements of Operations (unaudited) [Abstract]
Research and development expense	[2]	798	1,997	1,195	3,881	2,884
General and administrative expense	[2]	377	1,115	1,067	3,158	2,081
Sales and marketing expense	[2]	213	477	270	1,132	499
Loss from operations	[2]	(1,388)	(3,589)	(2,532)	(8,121)	(5,464)
Net loss	[2]	$ (1,392)	$ (3,804)	$ (2,543)	$ (8,509)	$ (5,471)
[1]	The condensed unaudited statement of operations information included in the table above reflects Asterias' results of operations for the three and six months ended June 30, 2017 and 2016. Although the periods shown are provided for comparative purposes only, the condensed results of operations of Asterias shown for the three and six months ended June 30, 2017 were not included in BioTime's condensed consolidated statements of operations. The unaudited results of operations of Asterias for the period January 1, 2016 through May 12, 2016 only are included in the unaudited condensed consolidated results of BioTime for the three and six months ended June 30, 2016 due to the Asterias Deconsolidation on May 13, 2016.
[2]	The condensed unaudited statements of operations information included in the table above for the period January 1, 2017 through February 16, 2017, and for the three and six months ended June 30, 2016, reflects OncoCyte results of operations included in BioTime's condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016, as applicable, respectively, after intercompany eliminations. The information for OncoCyte shown for the period from February 17, 2017 through June 30, 2017 is not included in BioTime's condensed consolidated statements of operations for the three and six months ended June 30, 2017, due to the OncoCyte Deconsolidation on February 17, 2017.

Equity Method Accounting for 33

Equity Method Accounting for Common Stock of Asterias, at fair value (Details) - Asterias Biotherapeutics, Inc. [Member] - USD ($) $ / shares in Units, $ in Thousands, shares in Millions		2 Months Ended	3 Months Ended		6 Months Ended
		Feb. 16, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016	May 13, 2016
Schedule of Equity Method Investments [Line Items]
Common stock, outstanding (in shares)									21.7
Fair value on investment			$ 77,200		$ 77,200			$ 100,000
Price per share on NYSE MKT (in dollars per share)			$ 3.55		$ 3.55		$ 3.40	$ 4.60
Unrealized gain (loss) on equity method investment			$ 3,300		$ (22,800)
Condensed Statements of Operations (unaudited) [Abstract]
Total revenue	[1]	$ 2,354	316	$ 1,532	2,326	$ 3,126
Gross profit	[1]	2,301	298	1,526	2,256	3,067
Loss from operations	[1]	(13,944)	(8,533)	(7,074)	(17,640)	(18,166)
Net loss	[1]	$ (13,113)	$ (8,728)	$ (5,159)	$ (15,015)	$ (15,496)
[1]	The condensed unaudited statement of operations information included in the table above reflects Asterias' results of operations for the three and six months ended June 30, 2017 and 2016. Although the periods shown are provided for comparative purposes only, the condensed results of operations of Asterias shown for the three and six months ended June 30, 2017 were not included in BioTime's condensed consolidated statements of operations. The unaudited results of operations of Asterias for the period January 1, 2016 through May 12, 2016 only are included in the unaudited condensed consolidated results of BioTime for the three and six months ended June 30, 2016 due to the Asterias Deconsolidation on May 13, 2016.

Property, plant and equipment34

Property, plant and equipment, net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017		Jun. 30, 2016	Dec. 31, 2016
Property, plant and equipment net [Abstract]
Accumulated depreciation and amortization	$ (2,777)	[1]		$ (2,980)
Property, plant and equipment, net	5,240	[1]		5,529
Depreciation and amortization expense	421		$ 748
Equipment, Furniture and Fixtures [Member]
Property, plant and equipment net [Abstract]
Property, plant and equipment	4,001	[1]		4,718
Leasehold Improvements [Member]
Property, plant and equipment net [Abstract]
Property, plant and equipment	4,016	[1]		$ 3,791
Depreciation and amortization expense	$ 421		$ 748
[1]	Reflects the effect of the OncoCyte Deconsolidation.

Intangible assets, net (Details

Intangible assets, net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017		Jun. 30, 2016	Dec. 31, 2016
Intangible assets, net [Abstract]
Intangible assets	$ 23,294	[1]		$ 25,703
Accumulated amortization	(15,230)	[1]		(15,497)
Intangible assets, net	8,064	[1]		$ 10,206
Amortization of intangible assets	$ 1,184		$ 2,292
[1]	Reflects the effect of the OncoCyte Deconsolidation.

Accounts Payable and Accrued 36

Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	[1]	Dec. 31, 2016
Accounts Payable and Accrued Liabilities [Abstract]
Accounts payable	$ 752		$ 1,593
Accrued expenses	2,385		3,212
Accrued compensation	1,461		1,904
Other current liabilities	532		435
Total	$ 5,130		$ 7,144
[1]	Reflects the effect of the OncoCyte Deconsolidation.

Related Party Transactions (Det

Related Party Transactions (Details)	6 Months Ended
	Jun. 30, 2017USD ($)ft²$ / shares	Jul. 10, 2017	Dec. 31, 2016USD ($)
Related Party Transaction [Line Items]
Carrying value of convertible notes	$ 0		$ 1,032,000
Rent per month	$ 5,050
Area of office space (in square feet) | ft²	900
OncoCyte [Member]
Related Party Transaction [Line Items]
Markup rate on allocated costs	5.00%
Interest rate charged on unpaid and overdue invoices	15.00%
Receivables from related party	$ 2,500,000
OncoCyte [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Term of payment	30 days
Asterias Biotherapeutics [Member]
Related Party Transaction [Line Items]
Proceeds from related party	$ 300,000
Ascendance Biotechnology, Inc [Member]
Related Party Transaction [Line Items]
Receivables from related party	200,000
Cell Cure Neurosciences, Ltd. [Member]
Related Party Transaction [Line Items]
Carrying value of convertible notes	2,555,000		1,865,000
Amount of convertible note	2,898,000		2,544,000
Unamortized debt discount	$ 343,000		$ 679,000
Cell Cure Neurosciences, Ltd. [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Ownership interest percentage		99.80%
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Stated interest rate	3.00%
Conversion price (in dollars per share) | $ / shares	$ 20
Accrued interest is payable period	3 years
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes Payable [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Estimated fair market value (in dollars per share) | $ / shares	$ 40
Intrinsic value (in dollars per share) | $ / shares	$ 20
Effective annual interest rate	23.00%
Cell Cure Neurosciences, Ltd. [Member] | Convertible Notes Payable [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Estimated fair market value (in dollars per share) | $ / shares	$ 28
Intrinsic value (in dollars per share) | $ / shares	$ 8
Effective annual interest rate	11.00%

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	Jul. 10, 2017	Jun. 06, 2017	Feb. 28, 2017	Jun. 30, 2017	Aug. 09, 2017	Apr. 06, 2017	Dec. 31, 2016	Mar. 31, 2016
Preferred Shares [Abstract]
Preferred shares, shares authorized (in shares)				2,000,000			2,000,000
Preferred shares, shares issued (in shares)				0			0
Preferred shares, shares outstanding (in shares)				0			0
Common Shares [Abstract]
Common stock, shares authorized (in shares)				150,000,000	150,000,000		150,000,000	125,000,000
Common stock, par value (in dollars per share)				$ 0			$ 0
Common stock, issued (in shares)				110,875,610			103,396,245
Common stock, outstanding (in shares)				110,875,610			102,776,539
Treasury stock (in shares)				0			619,706
Transfer of ownership at carrying value		$ 3,100,000
Subsequent Event [Member]
Common Shares [Abstract]
Common stock, shares authorized (in shares)					150,000,000
Common Stock [Member]
Common Shares [Abstract]
Number of shares sold (in shares)			7,453,704
Purchase price per share (in dollars per share)			$ 2.70
Proceeds from sale of stock			$ 18,500,000
Cell Cure Neurosciences, Ltd. [Member]
Common Shares [Abstract]
Ownership percentage				62.50%
Cell Cure Neurosciences, Ltd. [Member] | Subsequent Event [Member]
Common Shares [Abstract]
Ownership percentage	99.80%
Cell Cure Neurosciences, Ltd. [Member] | Common Stock [Member] | Subsequent Event [Member]
Common Shares [Abstract]
Number of shares sold (in shares)	4,924,542
Common shares issued value	$ 15,200,000
LifeMap Sciences, Inc. [Member]
Common Shares [Abstract]
Ownership percentage		82.00%					78.00%
LifeMap Solutions, Inc [Member]
Common Shares [Abstract]
Ownership percentage		100.00%
Cantor Fitzgerald & Co [Member]
Common Shares [Abstract]
Percentage of commission payable				3.00%
Cantor Fitzgerald & Co [Member] | Maximum [Member]
Common Shares [Abstract]
Aggregate offering price						$ 25,000,000

Stock Option Plans (Details)

Stock Option Plans (Details) - 2012 Plan [Member] - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for future issuance (in shares)	16,000,000
Shares Available for Grant [Rollforward]
Beginning of the period (in shares)	2,894,000
Increase to the 2012 Plan option pool (in shares)	6,000,000
Options granted (in shares)	(1,509,000)
Options exercised (in shares)	0
Options forfeited/cancelled (in shares)	410,000
End of the period (in shares)	7,795,000
Number of Options Outstanding [Rollforward]
Outstanding, beginning of the period (in shares)	6,958,000
Increase to the 2012 Plan option pool (in shares)	0
Options granted (in shares)	1,509,000
Options exercised (in shares)	(9,000)
Options forfeited/cancelled (in shares)	(590,000)
Outstanding, end of the period (in shares)	7,868,000
Options exercisable, end of period (in shares)	3,811,000
Number of RSUs Outstanding [Roll Forward]
Outstanding, beginning of the period (in shares)	100,000
Restricted stock units vested (in shares)	(25,000)
Outstanding, end of the period (in shares)	75,000
Weighted Average Exercise Price of Options [Rollforward]
Outstanding, beginning of the period (in dollars per share)	$ 3.60
Increase to the 2012 Plan option pool (in dollars per share)	0
Options granted (in dollars per share)	3.12
Options exercised (in dollars per share)	2.66
Options forfeited/cancelled (in dollars per share)	4.02
Outstanding end of the period (in dollars per share)	3.49
Options exercisable, end of period (in dollars per share)	$ 3.74
Weighted-average assumptions [Abstract]
Expected life	6 years 29 days	6 years 25 days
Risk-free interest rates	1.92%	1.45%
Volatility	59.80%	61.78%
Dividend yield	0.00%	0.00%

Stock Option Plans, Allocation

Stock Option Plans, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	$ 905	$ 2,220	$ 1,930	$ 5,593
Research and Development [Member]
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	166	579	496	1,785
General and Administrative [Member]
All stock-based compensation expense [Abstract]
Total stock-based compensation expense	$ 739	$ 1,641	$ 1,434	$ 3,808

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Deferred income tax expense (benefit), federal	$ (3.9)	$ 3.9	$ 0
Deferred income tax expense (benefit), state taxes	$ 0			$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2017USD ($)ft²Building	Dec. 31, 2016USD ($)
Operating Leased Assets [Line Items]
Restricted cash equivalents in escrow	$ 5,100,000	$ 0
Escrow liability	5,100,000	$ 0
AgeX Therapeutics, Inc [Member]
Operating Leased Assets [Line Items]
Restricted cash equivalents in escrow	5,100,000
Escrow liability	5,100,000
Cell Cure Neurosciences, Ltd. [Member]
Operating Leased Assets [Line Items]
Milestone payments	3,500,000
Accrued milestone payments	$ 0
Cell Cure Neurosciences, Ltd. [Member] | Minimum [Member]
Operating Leased Assets [Line Items]
Royalty revenue percentage	15.00%
Cell Cure Neurosciences, Ltd. [Member] | Maximum [Member]
Operating Leased Assets [Line Items]
Royalty revenue percentage	25.00%
New Alameda Lease [Member]
Operating Leased Assets [Line Items]
Leased area | ft²	30,795
Number of buildings for lease | Building	2
Lease term	7 years
Number of years lease can be extended	5 years
Lease commencement date	Feb. 1, 2016
Base rent	$ 64,670
Base rent increase rate	3.00%

Subsequent Events (Details)

Subsequent Events (Details) ₪ in Millions, $ in Millions	Aug. 08, 2017USD ($)	Aug. 08, 2017ILS (₪)	Jul. 10, 2017USD ($)shares	Feb. 28, 2017shares	Aug. 09, 2017shares	Jun. 30, 2017shares	Dec. 31, 2016shares	Mar. 31, 2016shares
Subsequent Event [Line Items]
Common stock, shares authorized (in shares)					150,000,000	150,000,000	150,000,000	125,000,000
Common Stock [Member]
Subsequent Event [Line Items]
Common shares issued (in shares)				7,453,704
Cell Cure Neurosciences, Ltd. [Member]
Subsequent Event [Line Items]
Ownership percentage, parent						62.50%
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares authorized (in shares)					150,000,000
Approved grant amount	$ 2	₪ 7.2
Subsequent Event [Member] | Cell Cure Neurosciences, Ltd. [Member]
Subsequent Event [Line Items]
Ownership percentage, parent			99.80%
Subsequent Event [Member] | Cell Cure Neurosciences, Ltd. [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common shares issued (in shares)			4,924,542
Common shares issued value | $			$ 15.2
Subsequent Event [Member] | Hadasit Bio-Holdings, Ltd [Member]
Subsequent Event [Line Items]
Ownership percentage, noncontrolling owners			21.20%